ANAVEX2-73

DRUG5 trials

Sponsors

Anavex Life Sciences Corp.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseParkinson Disease DementiaRett Syndrome

Phase 2

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT02756858

Anavex Life Sciences Corp.Alzheimer's Disease

Start: 2016-03-31End: 2020-11-30Updated: 2021-01-12

Study of ANAVEX2-73 in Patients With Rett Syndrome

CompletedNCT03758924

Anavex Life Sciences Corp.Rett Syndrome

Start: 2019-02-28End: 2020-10-30Updated: 2021-01-12

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

CompletedNCT04314934

Anavex Life Sciences Corp.Alzheimer Disease

Start: 2019-10-10End: 2024-06-14Updated: 2024-08-12

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

CompletedNCT04575259

Anavex Life Sciences Corp.Parkinson Disease Dementia

Start: 2019-10-10End: 2022-06-30Updated: 2022-08-01

Phase 3

ANAVEX2-73 Study in Patients With Rett Syndrome

CompletedNCT03941444

Anavex Life Sciences Corp.Rett Syndrome

Start: 2019-05-06End: 2021-09-30Updated: 2022-01-27

Related Papers

Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer's Disease: A Systematic Review.

2026-08-06

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.

2025-01-0123 citations

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

Alzheimer s & Dementia Translational Research & Clinical Interventions2020-01-0178 citations